Continuing Medical Education (CME) for KARE Plus, 2021 Edition
The American Society of Pediatric Hematology/Oncology (ASPHO) will offer CME credit for sessions viewed and self-assessment questions that are answered and evaluated. A certificate will be issued upon completion of the evaluation for each product.
The American Society of Pediatric Hematology/Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Society of Pediatric Hematology/Oncology designates this enduring material for a maximum of 66.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ASPHO offers its evaluation in an online format and it may be completed after viewing the sessions and answering the self-assessment questions in test mode. Partial CME is not offered for the KARE questions. Participants receive their certificates immediately when they submit their evaluation. We encourage all attendees to complete their evaluation regardless of whether they are seeking CME credit.
MOC Part 2
Purchasers will receive 33.25 MOC Part 2 points for the KARE questions once a score of 70% or higher is obtained at the completion of all self-assessment questions in test mode.
Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn 33.25 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.
Disclosure
ASPHO requires that planners and presenters disclose the existence of any relevant financial or other relationship they and/or their spouse/partner have with the manufacturers of any commercial interest (defined as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by or used on patients) whose products or services relate to the topics presented. ASPHO also requires disclosure of the intent to discuss unlabeled or investigational use(s) of a commercial product. The ASPHO Accreditation Subcommittee of the Education Committee reviews potential conflicts of interest as submitted by planners and presenters and resolves such conflicts to ensure the content of the activity is aligned with the interests of the public.
Speaker Disclosures:
No relevant financial relationships and no discussion of off-label drug use:
Michael Anderson, Rachel Bercovitz, Katharine Brock, Karen Effinger, Jason Fangusaro, Mark Fleming, Melissa Frei-Jones, Emily Greengard, Paul Harker-Murray, Jennifer Kesselheim, Elizabeth Mullen, Lauren Pommert, Carlos Rodriguez-Galindo, and Guy Young.
No relevant financial relationships; off-label drug use discussed:
Carl Allen, Elizabeth Fox, Cindy Neunert, Sung-Yun Pai, and David Walterhouse.
Relevant financial relationships and no discussion of off-label drug use:
Rachael Grace—Agios Pharmaceuticals, research funding; Julia Meade—AstraZeneca: Advisory Board, honorarium; Matthew Oberley—Caris Life Sciences: Executive Medical Director; Michael Pulsipher—Novartis: Steering Committee and Advisory Board, paid for time spent, Bellicum: educational talk, honorarium, Miltenyi: study support, honorarium, Adaptive: study support, paid for time spent, Jasper Therapeutics: consultant, paid for time spent; Zora Rogers—Novartis: consultant, honorarium.
Relevant financial relationships; off-label drug use discussed:
Denise Adams—Novartis: consultant, compensation, Venthura: consultant, compensation; Patrick Brown—Novartis: Scientific Advisory Board, honorarium, Servier: consulting, honorarium, Jazz: consulting, honorarium, Takeda: Scientific Advisory Board, honorarium; Mignon Loh—MediSix Therapeutics, consultant, honorarium; Kenneth McClain—SOBI Pharmaceuticals: Medical Advisory Board, honorarium; Sarah O’Brien—Bristol Myers Squib: study chair, salary support; Jacquelyn Powers—American Regent: site PI, research funding to institution.
Review Course Committee Disclosures:
No relevant financial relationships:
Nobuko Hijiya, Alex George, Julie Krystal, Sajad Khazal, Devang Pastakia, Anthony Audino, Ibrahim Ahmed, and Kayelyn Wagner.
Relevant financial relationships:
Paul Harker-Murray—Regeneron Pharmaceutical: consultation fee; Cindy Neunert—Sanofi-Genzyme: consultation fee; Jonathan Fish—Daiichi Sankyo: data monitoring committee membership, honorarium, Alexion Pharmaceuticals: data monitoring committee membership, honorarium; Stewart Goldman—AstraZeneca: speakers bureau, honorarium; Julia Meade—AstraZeneca: advisory board, honorarium; Michael A. Pulsipher—2202, 2205, and 2206 studies of CTL019: steering committee member, honorarium, Novartis: advisory board member, honorarium, Bellicum: speaker, honorarium, Milenti: speaker, honorarium, Jasper Therapeutics: consultant, honorarium.
Accreditation Subcommittee Disclosures:
No relevant financial relationships:
Glen Lew, Kate Mazur, Mary-Jane Hogan, Karen Lewing, Tanya Brown, Seethal Jacob, Cathleen Cook, Chandrika Gowda, and Mukta Sharma.
Staff Disclosures:
No relevant financial relationships:
Cassie McGarigle, Dominic Sawaya, and Ryan Wilkinson.
Disclaimer
The material presented in this activity represents the opinion of the speakers and not necessarily the views of ASPHO.